MX2021002428A - Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas. - Google Patents
Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas.Info
- Publication number
- MX2021002428A MX2021002428A MX2021002428A MX2021002428A MX2021002428A MX 2021002428 A MX2021002428 A MX 2021002428A MX 2021002428 A MX2021002428 A MX 2021002428A MX 2021002428 A MX2021002428 A MX 2021002428A MX 2021002428 A MX2021002428 A MX 2021002428A
- Authority
- MX
- Mexico
- Prior art keywords
- nash
- treatment
- anfg
- combinations
- related diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862726172P | 2018-08-31 | 2018-08-31 | |
| US201962883860P | 2019-08-07 | 2019-08-07 | |
| PCT/IB2019/057259 WO2020044266A1 (en) | 2018-08-31 | 2019-08-28 | Combinations for treatment of nash/nafld and related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021002428A true MX2021002428A (es) | 2023-01-02 |
Family
ID=68165623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021002428A MX2021002428A (es) | 2018-08-31 | 2019-08-28 | Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas. |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11254660B2 (https=) |
| EP (1) | EP3843740A1 (https=) |
| JP (1) | JP7161605B2 (https=) |
| KR (1) | KR102614808B1 (https=) |
| CN (1) | CN112955147A (https=) |
| AU (1) | AU2019329884B2 (https=) |
| BR (1) | BR112021003039A2 (https=) |
| CA (1) | CA3110601C (https=) |
| CL (1) | CL2021000491A1 (https=) |
| CO (1) | CO2021002230A2 (https=) |
| CR (1) | CR20210110A (https=) |
| DO (1) | DOP2021000036A (https=) |
| EC (1) | ECSP21012501A (https=) |
| IL (1) | IL281093B2 (https=) |
| MA (1) | MA53496A (https=) |
| MX (1) | MX2021002428A (https=) |
| PH (1) | PH12021550339A1 (https=) |
| PY (1) | PY1972032A (https=) |
| SG (1) | SG11202101503RA (https=) |
| TW (1) | TWI718644B (https=) |
| UY (1) | UY38351A (https=) |
| WO (1) | WO2020044266A1 (https=) |
| ZA (1) | ZA202101090B (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11590161B2 (en) * | 2018-08-13 | 2023-02-28 | Viscera Labs, Inc. | Therapeutic composition and methods |
| CR20210341A (es) * | 2018-11-22 | 2021-11-25 | Qilu Regor Therapeutics Inc | Agonistas de glp-ir y usos de los mismos |
| EP3906022A1 (en) * | 2018-12-31 | 2021-11-10 | Coherus Biosciences, Inc. | Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) |
| AU2020209216A1 (en) | 2019-01-18 | 2021-08-26 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
| SG11202107614PA (en) | 2019-01-18 | 2021-08-30 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| CN119841865A (zh) | 2020-02-07 | 2025-04-18 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| JP2021134211A (ja) * | 2020-02-24 | 2021-09-13 | ファイザー・インク | Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ |
| JP2022058085A (ja) * | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ |
| CN115335055A (zh) * | 2020-03-11 | 2022-11-11 | 东亚St株式会社 | 用于预防或治疗非酒精性脂肪性肝炎的药物组合物 |
| WO2021211959A2 (en) * | 2020-04-18 | 2021-10-21 | Inipharm, Inc. | Methods and compositions for treating drug induced steatohepatitis |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| FI4143183T3 (fi) | 2020-04-29 | 2026-01-07 | Gasherbrum Bio Inc | Heterosyklisiä glp-1-agonisteja |
| CN113816948B (zh) * | 2020-06-19 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 |
| PE20231181A1 (es) | 2020-08-06 | 2023-08-11 | Gasherbrum Bio Inc | Agonistas del glp-1 heterociclicos |
| PE20231206A1 (es) * | 2020-08-21 | 2023-08-17 | Terns Pharmaceuticals Inc | Compuestos como agonistas de glp-1r |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| CN112635049A (zh) * | 2020-12-23 | 2021-04-09 | 无锡市第二人民医院 | 一种研究HSD17B13 rs72613567基因变异和肾功能损伤之间关系的方法 |
| KR20240068737A (ko) | 2021-09-27 | 2024-05-17 | 테른스 파마슈티칼스, 인크. | Glp-1r 효능제로서의 벤즈이미다졸 카복실산 |
| AU2022375634A1 (en) | 2021-10-25 | 2024-06-06 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| KR20240150488A (ko) | 2022-02-23 | 2024-10-15 | 테른스 파마슈티칼스, 인크. | Glp-1r 작용제로서의 화합물 |
| CN119137124A (zh) | 2022-03-09 | 2024-12-13 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| JP2026501171A (ja) | 2022-12-15 | 2026-01-14 | ガシャーブラム・バイオ・インコーポレイテッド | Ｇｌｐ－１アゴニスト活性を有する化合物の塩および固体形態 |
| US20240398794A1 (en) | 2023-04-07 | 2024-12-05 | Terns Pharmaceuticals, Inc. | COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF |
| US20250017938A1 (en) * | 2023-06-20 | 2025-01-16 | Sagimet Biosciences Inc. | Combination therapies of fasn inhibitors with thyroid hormone receptor agonists |
| WO2025080818A1 (en) * | 2023-10-10 | 2025-04-17 | Sagimet Biosciences Inc. | Combinations of fasn inhibitors and glp-1 agonists for liver diseases |
| CN118787746B (zh) * | 2024-07-01 | 2025-09-16 | 安徽省立医院(中国科学技术大学附属第一医院) | 脂肪酸合成酶抑制剂在预防及治疗药物性肝损伤中的应用 |
| CN120698959B (zh) * | 2025-05-29 | 2026-01-23 | 河北医科大学 | 一种达格列净-依折麦布共无定形物及其制备方法和应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| DE3065190D1 (en) | 1979-11-05 | 1983-11-10 | Beecham Group Plc | Enzyme derivatives, and their preparation |
| DE3438830A1 (de) | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
| KR0182801B1 (ko) | 1991-04-16 | 1999-05-01 | 아만 히데아키 | 고체 분산체의 제조방법 |
| US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| JP3265680B2 (ja) | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| DE19504832A1 (de) | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| ATE364374T1 (de) | 1997-08-11 | 2007-07-15 | Pfizer Prod Inc | Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit |
| WO2000001389A1 (en) | 1998-07-06 | 2000-01-13 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| IL157253A0 (en) | 2001-02-28 | 2004-02-19 | Merck & Co Inc | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| NZ534582A (en) | 2002-02-27 | 2006-03-31 | Pfizer Prod Inc | ACC inhibitors |
| KR100869616B1 (ko) | 2004-05-12 | 2008-11-21 | 화이자 프로덕츠 인코포레이티드 | 프롤린 유도체 및 그의 다이펩티딜 펩티다제－ｉｖ저해제로서의 용도 |
| UA84208C2 (en) | 2004-05-25 | 2008-09-25 | Пфайзер Продактс Инк. | Tetraazabenzo(e)azulene derivatives and analogs thereof |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| JP5190448B2 (ja) | 2006-04-20 | 2013-04-24 | ファイザー・プロダクツ・インク | グルコキナーゼ仲介疾患を予防および治療するための縮合フェニルアミド複素環化合物 |
| EA200900613A1 (ru) | 2006-11-29 | 2009-10-30 | Пфайзер Продактс Инк. | Спирокетоновые ингибиторы ацетил-коа-карбоксилаз |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| WO2009144554A1 (en) | 2008-05-28 | 2009-12-03 | Pfizer, Inc. | Pyrazolospiroketone acetyl-c0a carboxylase inhibitors |
| US20110009443A1 (en) | 2008-05-28 | 2011-01-13 | Kevin Daniel Freeman-Cook | Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors |
| EP2318370A1 (en) | 2008-07-29 | 2011-05-11 | Pfizer Inc. | Fluorinated heteroaryls |
| MY155418A (en) | 2008-08-28 | 2015-10-15 | Pfizer | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
| WO2010086820A1 (en) | 2009-02-02 | 2010-08-05 | Pfizer Inc. | 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof |
| US20110319379A1 (en) | 2009-03-11 | 2011-12-29 | Corbett Jeffrey W | Substituted Indazole Amides And Their Use As Glucokinase Activators |
| MY151246A (en) | 2009-03-11 | 2014-04-30 | Pfizer | Benzofuranyl derivatives |
| WO2010106457A2 (en) | 2009-03-20 | 2010-09-23 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonanes |
| CA2759843A1 (en) | 2009-05-08 | 2010-11-10 | Pfizer Inc. | Gpr 119 modulators |
| WO2010128414A1 (en) | 2009-05-08 | 2010-11-11 | Pfizer Inc. | Gpr 119 modulators |
| NZ596467A (en) | 2009-06-05 | 2014-01-31 | Pfizer | L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators |
| WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
| CH702192A1 (de) | 2009-11-04 | 2011-05-13 | New Dent Ag | Keramisches Implantat. |
| HRP20161178T1 (hr) * | 2010-09-30 | 2016-11-04 | Pfizer Inc. | N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE |
| CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| JP2018501276A (ja) | 2015-01-09 | 2018-01-18 | ギリアド アポロ， エルエルシー | 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法 |
| SI3397631T1 (sl) * | 2015-12-29 | 2022-01-31 | Pfizer Inc. | Substituirani 3-azabiciklo(3.1.0)heksani kot zaviralci ketoheksokinaze |
| AR109179A1 (es) * | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| CN106271089B (zh) | 2016-09-30 | 2019-01-25 | 英诺激光科技股份有限公司 | 一种激光薄膜刻蚀装置及方法 |
| EP3555064B9 (en) | 2016-12-16 | 2023-03-01 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| FI3713942T3 (fi) | 2017-11-21 | 2023-05-04 | Pfizer | 4-(4-(1-isopropyyli-7-okso-1,4,6,7-tetrahydrospiro[indatsoli-5,4'-piperidiini]-1'-karbonyyli)-6-metoksipyridin-2-yyli)bentsoehapon kiteinen 2-amino-2-(hydroksimetyyli)propaani-1,3-diolisuola |
-
2019
- 2019-08-28 CR CR20210110A patent/CR20210110A/es unknown
- 2019-08-28 MA MA053496A patent/MA53496A/fr unknown
- 2019-08-28 US US16/553,818 patent/US11254660B2/en active Active
- 2019-08-28 CN CN201980071389.XA patent/CN112955147A/zh active Pending
- 2019-08-28 EP EP19783644.8A patent/EP3843740A1/en active Pending
- 2019-08-28 IL IL281093A patent/IL281093B2/en unknown
- 2019-08-28 BR BR112021003039-5A patent/BR112021003039A2/pt unknown
- 2019-08-28 AU AU2019329884A patent/AU2019329884B2/en active Active
- 2019-08-28 MX MX2021002428A patent/MX2021002428A/es unknown
- 2019-08-28 SG SG11202101503RA patent/SG11202101503RA/en unknown
- 2019-08-28 KR KR1020217009415A patent/KR102614808B1/ko active Active
- 2019-08-28 JP JP2021510174A patent/JP7161605B2/ja active Active
- 2019-08-28 WO PCT/IB2019/057259 patent/WO2020044266A1/en not_active Ceased
- 2019-08-28 CA CA3110601A patent/CA3110601C/en active Active
- 2019-08-28 TW TW108130771A patent/TWI718644B/zh active
- 2019-08-29 UY UY0001038351A patent/UY38351A/es not_active Application Discontinuation
- 2019-08-30 PY PY201901972032A patent/PY1972032A/es unknown
-
2021
- 2021-02-17 ZA ZA2021/01090A patent/ZA202101090B/en unknown
- 2021-02-17 PH PH12021550339A patent/PH12021550339A1/en unknown
- 2021-02-23 EC ECSENADI202112501A patent/ECSP21012501A/es unknown
- 2021-02-23 CO CONC2021/0002230A patent/CO2021002230A2/es unknown
- 2021-02-25 DO DO2021000036A patent/DOP2021000036A/es unknown
- 2021-02-26 CL CL2021000491A patent/CL2021000491A1/es unknown
- 2021-10-11 US US17/498,256 patent/US12247022B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TWI718644B (zh) | 2021-02-11 |
| EP3843740A1 (en) | 2021-07-07 |
| KR102614808B1 (ko) | 2023-12-19 |
| AU2019329884A1 (en) | 2021-03-11 |
| CN112955147A (zh) | 2021-06-11 |
| IL281093B1 (en) | 2025-07-01 |
| CA3110601A1 (en) | 2020-03-05 |
| US20220023299A1 (en) | 2022-01-27 |
| JP7161605B2 (ja) | 2022-10-26 |
| CL2021000491A1 (es) | 2021-08-20 |
| MA53496A (fr) | 2021-12-08 |
| CO2021002230A2 (es) | 2021-03-08 |
| IL281093A (en) | 2021-04-29 |
| US11254660B2 (en) | 2022-02-22 |
| US12247022B2 (en) | 2025-03-11 |
| CR20210110A (es) | 2021-05-13 |
| SG11202101503RA (en) | 2021-03-30 |
| TW202026292A (zh) | 2020-07-16 |
| ZA202101090B (en) | 2022-06-29 |
| JP2021535126A (ja) | 2021-12-16 |
| PY1972032A (es) | 2021-06-03 |
| BR112021003039A2 (pt) | 2021-05-18 |
| AU2019329884B2 (en) | 2022-01-27 |
| KR20210053929A (ko) | 2021-05-12 |
| PH12021550339A1 (en) | 2021-10-04 |
| WO2020044266A1 (en) | 2020-03-05 |
| IL281093B2 (en) | 2025-11-01 |
| CA3110601C (en) | 2023-09-05 |
| US20200071306A1 (en) | 2020-03-05 |
| UY38351A (es) | 2020-03-31 |
| DOP2021000036A (es) | 2021-04-15 |
| ECSP21012501A (es) | 2021-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021002428A (es) | Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas. | |
| ZA202500997B (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| BR112013029246A2 (pt) | 4-amino-5-flúor-3-[6- (4-metilpiperazin- 1 - il) - 1h - benzimidazol - 2 - il] - 1h - quinolin-2-ona para uso no tratamento de carcinoma adenoide cístico | |
| PH12018500532A1 (en) | 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| PH12016500024A1 (en) | Bromodomain inhibitor | |
| EP4342540A3 (en) | Substituted heterocyclyl derivatives as cdk inhibitors | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| WO2017132432A8 (en) | Benzimidazole derivatives as modulators of ror-gamma | |
| PH12018500957A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| WO2016109217A3 (en) | Btk inhibitors | |
| BR112015030578A2 (pt) | combinações farmacêuticas | |
| BR112018015718A2 (pt) | utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash) | |
| JOP20190209A1 (ar) | مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان | |
| MX2019004375A (es) | Inhibidores de bromodominios. | |
| MA39448B1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
| BR112015030953A8 (pt) | compostos de piridina fundidos de heterociclo de cinco membros, método de produzir os mesmos, e uso dos mesmos | |
| EA202190367A1 (ru) | Комбинации для лечения nash/nafld и родственных заболеваний | |
| EA201690762A1 (ru) | {4-[5-(3-хлорфенокси)оксазоло[5,4-d]пиримидин-2-ил]-2,6-диметилфенокси}уксусная кислота для применения при предупреждении или лечении острого повреждения почек | |
| BR112017021374A2 (pt) | ácido pirrolidona carboxílico (pca) para uso oftálmico | |
| PH12020551493A1 (en) | Triazacyclododecansulfonamide (``tcd``)-based protein secretion inhibitors | |
| WO2013151719A3 (en) | Fluorinated oxazolidinone derivatives | |
| BR112018068170A2 (pt) | ácido (2s,4r)-5-(5?-cloro-2?-fluor-[1,1?-bifenil]-4-il)-2-(etoximetil)-4-(3-hidroxi-isoxazol-5-carboxamido)-2-metilpentanoico cristalino e usos dos mesmos | |
| UA118075C2 (uk) | Лікарський засіб у формі концентрату для приготування інфузійного розчину |